{"ticker": {"uuid": "e81978a5-f0f2-4b6f-b1a9-a69909ca1200", "symbol": "688136", "name": "Kexing Biopharm Co., Ltd.", "exchange": "SHH", "country": "CN", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ETFs Investing in Kexing Biopharm Co., Ltd. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE0zNHhtWVM4N1RiM29zYms2cmpLa05aNGZjdHFsMms2QTljRFFpQXEtV05OMlBxc0p0dFVmdFdNRFJtZVN1d1BJNS10eUd5QXA3cFNWN3YwakV3SGJPZkRRREdB?oc=5", "source_name": "TradingView", "published_at": "2026-07-14T07:14:39+00:00", "published_display": "14 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxOaWh0RlZzWmh4X1FQek5wRkI1Vi1sR2pKa3dVTkJpdk12LTU0cTNldU9yLXB3RGdVNUhwcmpKLTdJaGYxSEhHQk95OU1uQmpKWG5MSmc0bFNDaDI3TTVQeDIyTndFSTRNU2JBY1lZUTNFR0xLMFkzWDBGTWZzQldEWEdFSktXU0lNVlNiaG8yRWNQOUtIeTBha1ZVaFFLbkNJYjhnaWlZZEtRdXJJV1dwUzd3SEdLMEVESzVEZTB2YjUyeFk5WkVwcnhERG1YVDA3NWlzQ1czTTNUWnVXQl9IdjNxMThVQTRiSmFEbjZOeENxcXJod2tHOHlsVWJ2NHJqZVRYYnNTWFAwZ0lINlM1bV9DQmJ2QQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQdUVyX29kX2RPOFptaW5PZWQ1TjVIX3pnRXhqQ0tFQUMyM1BiaF84LVpKb2RDeS02dnJjaFRoUFBBaHlwSUhVTzhlenRkcTFIY1QtaGFqLUNJWk43c3FHQUZHcHFkbHNkNVlWT04waHlaY3U4M2dOV3BLWHYzdWlTS0Rjd0E0ZzEwRUJZYnd1dzBkQkhCY2gwUTlBSUVjNDNZLTByNTlfalpXaFNXVkg5aTcyRGY5NVQ4TXhILVJzemFRRm5lMXN6a2ZJT0lIcGNTeld5UThpVlZ5TVJOZEwwQ2s3ZWRKWVJPNWhkVmFZY3pKRzg?oc=5", "source_name": "Macau Business", "published_at": "2025-09-12T07:00:00+00:00", "published_display": "12 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kexing Biopharm Receives FDA Approval for Clinical Trials of GB05 Inhalation Therapy for Pediatric RSV Infections", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPSWhfbnlCRHV0allSMmtBa1pVYWkyRmlLaGZMa0dOZ0E1OEdvdEdSeHdHeHBWWWtKb3NCMUdSYWQtS0RuS0dkN1JOWDVVVDJMZk1OaEFJbUx5X0tvRUNnUTg2SXF0eGJlbTVCbzlad1R5YVlXZGY5dGZqa2NKTDdTdjNUUVNLMC05UkJTU3hVWjdSSEZmOEowWnVzMHo5M0s4cEpVOXp6d05DNExWT0Myd2w0ZnZVWlNVMDhLX1VKSlM5d1hpRVlmblFmclo0UU9JWVJUakJBSFVDcG9sclZEcXFrWjNTX1FKWDRYWm53?oc=5", "source_name": "BioPharma APAC", "published_at": "2025-02-17T08:00:00+00:00", "published_display": "17 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Completion of PIC/S Participating Authorities' Audits of Kexing Biopharm's Licensed Product Infliximab for Injection", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOTHVBZ3ROQzRPSU1rSTFoNjdOenRkSGxIUTRjZEtSQU8xQ0pUWjMzN3YtTDR0TTVpQkRZSHBPQ1V0NWRxaTNfSno0UUhpY3FOdV96cUNrRHBXNWpHQmVUZEstWVVtOU9ibEhpdWY2RWRDSDI0d2tndnA5ZEpCM2FHNjhZNTl1d1BwOHdLTHI2LS02Ny12NHJzQUhxQVA0TUQ0OW9oRjdSeUN1djBMa29xb1ItWWtURjE2UU0wdHZ0Q21LTG94bXZ1LWdKc3JhYTJXVUUxeWZnYURJeFJsSUdya1lwN1NFRDZM?oc=5", "source_name": "The Kingston Whig Standard", "published_at": "2024-04-02T07:00:00+00:00", "published_display": "02 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kexing Biopharm Obtains the Products of Trastuzumab and Neratinib Maleate Tablets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPSV9EeEs0eHdZbGlqeFB2amt1NXZaT0tVc1lLdDlfeVZQQURWbmxQbXRqZDZyZjZINHhSRU5PVWJjNlpfX3VHc2h3MkZSYzl6Sl9KakxLTV9SZWdYOTRrbV9ZMDlUREVGaHRuMTFJVmdMUzZPMzBIOGdiNUlZbjBDMGJwYzJjSXZrcVNmYnZLZFFQenhCSEZjZmF0VWxUb3RNaXdod0tBREFsMFdiSUdhNy1rVDFsQ3hDRzJqTGtR?oc=5", "source_name": "The Kingston Whig Standard", "published_at": "2023-06-26T07:00:00+00:00", "published_display": "26 Jun 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ETFs Investing in Kexing Biopharm Co., Ltd. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE0zNHhtWVM4N1RiM29zYms2cmpLa05aNGZjdHFsMms2QTljRFFpQXEtV05OMlBxc0p0dFVmdFdNRFJtZVN1d1BJNS10eUd5QXA3cFNWN3YwakV3SGJPZkRRREdB?oc=5", "source_name": "TradingView", "published_at": "2026-07-14T07:14:39+00:00", "published_display": "14 Jul 2026 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxOaWh0RlZzWmh4X1FQek5wRkI1Vi1sR2pKa3dVTkJpdk12LTU0cTNldU9yLXB3RGdVNUhwcmpKLTdJaGYxSEhHQk95OU1uQmpKWG5MSmc0bFNDaDI3TTVQeDIyTndFSTRNU2JBY1lZUTNFR0xLMFkzWDBGTWZzQldEWEdFSktXU0lNVlNiaG8yRWNQOUtIeTBha1ZVaFFLbkNJYjhnaWlZZEtRdXJJV1dwUzd3SEdLMEVESzVEZTB2YjUyeFk5WkVwcnhERG1YVDA3NWlzQ1czTTNUWnVXQl9IdjNxMThVQTRiSmFEbjZOeENxcXJod2tHOHlsVWJ2NHJqZVRYYnNTWFAwZ0lINlM1bV9DQmJ2QQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQdUVyX29kX2RPOFptaW5PZWQ1TjVIX3pnRXhqQ0tFQUMyM1BiaF84LVpKb2RDeS02dnJjaFRoUFBBaHlwSUhVTzhlenRkcTFIY1QtaGFqLUNJWk43c3FHQUZHcHFkbHNkNVlWT04waHlaY3U4M2dOV3BLWHYzdWlTS0Rjd0E0ZzEwRUJZYnd1dzBkQkhCY2gwUTlBSUVjNDNZLTByNTlfalpXaFNXVkg5aTcyRGY5NVQ4TXhILVJzemFRRm5lMXN6a2ZJT0lIcGNTeld5UThpVlZ5TVJOZEwwQ2s3ZWRKWVJPNWhkVmFZY3pKRzg?oc=5", "source_name": "Macau Business", "published_at": "2025-09-12T07:00:00+00:00", "published_display": "12 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kexing Biopharm Receives FDA Approval for Clinical Trials of GB05 Inhalation Therapy for Pediatric RSV Infections", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxPSWhfbnlCRHV0allSMmtBa1pVYWkyRmlLaGZMa0dOZ0E1OEdvdEdSeHdHeHBWWWtKb3NCMUdSYWQtS0RuS0dkN1JOWDVVVDJMZk1OaEFJbUx5X0tvRUNnUTg2SXF0eGJlbTVCbzlad1R5YVlXZGY5dGZqa2NKTDdTdjNUUVNLMC05UkJTU3hVWjdSSEZmOEowWnVzMHo5M0s4cEpVOXp6d05DNExWT0Myd2w0ZnZVWlNVMDhLX1VKSlM5d1hpRVlmblFmclo0UU9JWVJUakJBSFVDcG9sclZEcXFrWjNTX1FKWDRYWm53?oc=5", "source_name": "BioPharma APAC", "published_at": "2025-02-17T08:00:00+00:00", "published_display": "17 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Completion of PIC/S Participating Authorities' Audits of Kexing Biopharm's Licensed Product Infliximab for Injection", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOTHVBZ3ROQzRPSU1rSTFoNjdOenRkSGxIUTRjZEtSQU8xQ0pUWjMzN3YtTDR0TTVpQkRZSHBPQ1V0NWRxaTNfSno0UUhpY3FOdV96cUNrRHBXNWpHQmVUZEstWVVtOU9ibEhpdWY2RWRDSDI0d2tndnA5ZEpCM2FHNjhZNTl1d1BwOHdLTHI2LS02Ny12NHJzQUhxQVA0TUQ0OW9oRjdSeUN1djBMa29xb1ItWWtURjE2UU0wdHZ0Q21LTG94bXZ1LWdKc3JhYTJXVUUxeWZnYURJeFJsSUdya1lwN1NFRDZM?oc=5", "source_name": "The Kingston Whig Standard", "published_at": "2024-04-02T07:00:00+00:00", "published_display": "02 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kexing Biopharm Obtains the Products of Trastuzumab and Neratinib Maleate Tablets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPSV9EeEs0eHdZbGlqeFB2amt1NXZaT0tVc1lLdDlfeVZQQURWbmxQbXRqZDZyZjZINHhSRU5PVWJjNlpfX3VHc2h3MkZSYzl6Sl9KakxLTV9SZWdYOTRrbV9ZMDlUREVGaHRuMTFJVmdMUzZPMzBIOGdiNUlZbjBDMGJwYzJjSXZrcVNmYnZLZFFQenhCSEZjZmF0VWxUb3RNaXdod0tBREFsMFdiSUdhNy1rVDFsQ3hDRzJqTGtR?oc=5", "source_name": "The Kingston Whig Standard", "published_at": "2023-06-26T07:00:00+00:00", "published_display": "26 Jun 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 60, "total_relevant": 6, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 5, "score": 53, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 19.2, "latest_week": "2026-07-17", "one_week_move": -10.4, "four_week_move": 5.0, "twelve_week_move": -32.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.580597, "market_dynamics_buy_signal": false, "relative_strength": -39.59776, "fair_value_gap": -23.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.1277, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.4% over one week, +5.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "The Kingston Whig Standard", "count": 2}, {"label": "TradingView", "count": 1}, {"label": "Business Wire", "count": 1}, {"label": "Macau Business", "count": 1}, {"label": "BioPharma APAC", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 4}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.4% over one week, +5.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ETFs Investing in Kexing Biopharm Co., Ltd. Class A Stocks"}], "updated_at": "2026-07-21T23:02:52.889912+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}